New Mucon Series K2P Powered Iris Valve Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Mucon Series K2P Powered Iris Valve Technology

Mucon a division of Process Components Ltd has launched its new Series K2P electrically / pneumatically actuated range of Iris valves. The Mucon brand of Iris diaphragm valves has for over sixty years been associated with the control of powders, granules, capsules and pellets to the Pharmaceutical, Chemical and Food processing sectors.
Now in its second generation, the Series K2 Powered Iris Valves have been specifically designed for automatic and remote applications, complimenting the popular hand operated versions.

Developed for applications requiring a high level of hygiene, this valve utilises our patented, moulded diaphragm technology already employed throughout the K-Valve range.

Mucon Engineers have taken great care to balance customer requirements for quick disconnect, ease of cleaning and hygienic design with the requirements for reliability and control system integration.

All body parts are manufactured from 316 stainless steel, as standard. White moulded diaphragms of Natural Rubber, EPDM and Silicone are all manufactured from FDA approved materials.

The salient features and benefits of the new MUCON K2P valve are as follows;

  • Extensively used in the Pharmaceutical, Chemical and Food sectors
  • FDA approved diaphragm materials
  • Full product flow control
  • Non-Jamming
  • No mechanical parts in contact with the product
  • Slim Design
  • Electric and Pneumatic actuation
  • ATEX approved Cat. 1D / 2D
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
FindPharma Custom Search

Click here